
According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Abiomed is not utilizing their capital as effectively as possible. Abiomed reached earnings of $56.95 million and sales of $248.14 million in Q2.